Navigation Links
ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants

it is possible that ANA380/LB80380 used in combination with these existing drugs may help prevent the emergence of resistance. These new results are also consistent with previously reported clinical data showing that ANA380 is active in patients refractory to lamivudine."

"Clearly, we are encouraged by these study results and believe they support additional clinical evaluation to confirm the potential broad clinical utility of ANA380 in treating patients with chronic HBV infection," said In-Chull Kim, Ph.D., President and Chief Executive Officer of LG Life Sciences.

Anadys and LG Life Sciences entered into a Joint Development and License Agreement in April 2004 providing for the global development of ANA380 and pursuant to which Anadys acquired commercialization rights to ANA380 in North America, Europe, Japan and the rest of the world other than China, Korea, India and countries in Southeast Asia. Next steps for the program, including a proposed Phase IIb dose selection clinical trial, are under discussion between Anadys and LGLS.

Study Methods

HBV mutant strains were generated from a wild-type strain of HBV genotype D through site-directed mutagenesis. Mutant strains encoded polymerases resistant to lamivudine, adefovir, entecavir or telbivudine. Replicate HepG2 cell cultures were infected with HBV DNA using baculovirus vectors and were exposed to different concentrations of each drug for seven days. Viral DNA then was extracted and quantified. EC50 values, which were calculated from averages of three independent experiments, were used to evaluate susceptibility.

Clinical Background

ANA380 is an oral prodrug of ANA317 (LB80317), a nucleotide analog. Data from 62 HBV infected patients from a previous Phase II study showed that patients treated daily with ANA380 at 90 mg, 150 mg and 240 mg dose levels experienced reduction in plasma HBV viral DNA at 12 weeks of 3.9 log10, 3.9 log10 and 4.1 log10 units, respectively, (greate
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
2. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
3. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
6. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
7. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
(Date:9/15/2014)... SALT LAKE CITY , Sept. 15, 2014 ... polymer solutions to the medical device market, announced ... creation of Biomerics Advanced Catheter Division. The new division ... minimally invasive surgical device solutions for the structure ... markets. Biomerics Advanced Catheter will ...
(Date:9/15/2014)... Mass. , Sept. 15, 2014  Decision Resources ... armamentarium continues to expand, increasing pressure to control expenditures ... Interviewed payers emphasize that although type 2 diabetes drugs ... formularies are likely to enforce additional restrictions on expensive ... France , Germany , ...
(Date:9/15/2014)... LAKE CITY , Sept. 15, 2014 /PRNewswire-iReach/ ... minimally invasive surgical (MIS) visualization products, is pleased ... certification for its quality management system (QMS) through ... another important step in Olive Medical complying with ... medical devices.  It is the goal of Olive ...
Breaking Medicine Technology:Biomerics and Access Point Technologies OEM Announce Merger and Creation of Biomerics Advanced Catheter Division 2Interviewed Payers in the EU5 Anticipate Increasing Prescribing Constraints for Premium-Priced Type 2 Diabetes Agents 2Interviewed Payers in the EU5 Anticipate Increasing Prescribing Constraints for Premium-Priced Type 2 Diabetes Agents 3Olive Medical Achieves ISO 13485:2003 Certification 2
... Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) ... financial results will be released on Friday, February 25, ... John H. Johnson, Chief Executive Officer, and David Gionco, ... an investment community conference call and webcast at 9:00 ...
... Perrigo (Nasdaq: PRGO ; TASE) today announced that ... to sell and distribute blood glucose monitors and test strips ... agreement, Perrigo will sell and distribute certain products in the ... AgaMatrix is a privately held company focused entirely on innovative ...
Cached Medicine Technology:Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2010 Results Conference Call on Friday, February 25, 2011 2Perrigo Enters Into Exclusive Sales and Distribution Agreement With AgaMatrix for Store Brand Blood Glucose Monitoring Products 2Perrigo Enters Into Exclusive Sales and Distribution Agreement With AgaMatrix for Store Brand Blood Glucose Monitoring Products 3
(Date:9/15/2014)... York, NY (PRWEB) September 15, 2014 ... Ariana Grande concert tickets for her 2015 Honeymoon Tour. ... The 21-year-old native of Boca Raton, Florida has been active ... released her first album, which reached the top of the ... the Recording Industry Association of America for selling more than ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 Today, Zane ... on Zions Bank’s Speaking on Business radio show. ... consumer product, so employers know it doesn’t make sense ... Benefits can also save the employer and employee as ... The host of Zions Bank's Speaking on Business ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 Ondine ... Nicolas Loebel, its President and Chief Technology Officer, ... on Photodynamic Therapy (PDT) and Photodiagnosis in Clinical ... in Brixen/Bressanone (Italy) from October 14-18, 2014 alongside ... Medicine on October 13-14th, is an annual conference ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 Transvaginal mesh ... continue to move forward in the federal multidistrict litigation ... West Virginia, Bernstein Liebhard LLP reports. According to documents ... Order on September 10th that provides for the severance ... that none of the affected plaintiffs has objected to ...
(Date:9/15/2014)... Randy Dotinga HealthDay Reporter ... Patients prescribed cholesterol-lowering drugs are more likely to fill ... are cheaper generic brands, new research suggests. At ... brands include Crestor, Zocor and Lipitor. Generic statins are ... risk of heart problems due to clogged arteries. ...
Breaking Medicine News(10 mins):Health News:Ariana Grande Tickets in Fairfax, Uncasville, Philadelphia, Orlando, San Jose, Miami, New York, Detroit, Saint Paul, Chicago, San Antonio, Pittsburgh, Atlanta & Dallas 2Health News:Ariana Grande Tickets in Fairfax, Uncasville, Philadelphia, Orlando, San Jose, Miami, New York, Detroit, Saint Paul, Chicago, San Antonio, Pittsburgh, Atlanta & Dallas 3Health News:Zane Benefits Featured on Zions Bank Speaking on Business 2Health News:Ondine Presenting at the 2014 International Symposium on Photodynamic Therapy and Photodiagnosis 2Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:Older Patients More Likely to Fill Prescriptions for Generic Statins: Study 2Health News:Older Patients More Likely to Fill Prescriptions for Generic Statins: Study 3
... colonised by E. coli bacteria early in life have ... a study of infants carried out at the Sahlgrenska Academy at ... outnumber the cells in our bodies by a factor of ten ... maturation of the immune system. The normal bacterial flora in the ...
... 2012) Autism Speaks is pleased to announce the launch ... in Toddlers, or M-CHAT. The M-CHAT is a scientifically validated ... age to assess their risk for autism spectrum disorder (ASD). ... Fein, Ph.D. and clinical psychologist Marianne Barton, Ph.D. The American ...
... Scientists who found a way to make white fat behave ... new obesity treatments. Brown fat burns energy (preventing obesity), ... cells are associated with fat accumulation around organs in the ... an increased risk for diabetes and heart disease, the researchers ...
... participation in a brief training program designed to ... in how patients perceived their interactions with the ... empathy with patients usually drops during medical school ... of Massachusetts General Hospital (MGH) researchers will appear ...
... against serious pneumococcal disease does not offer full protection, ... of Gothenburg, Sweden, finding that the number of cases ... Each year an estimated 1 million children worldwide die ... those in poor countries, but pneumococcal bacteria cause disease ...
... 6, 2012) - Eye color may be an indicator of ... A study, led by the University of Colorado School of ... have vitiligo. It then follows, according to scientists, that people ... Vitiligo is an autoimmune skin disease in which pigment loss ...
Cached Medicine News:Health News:Gut flora affects maturation of B cells in infants 2Health News:Automated autism screening tool available on Autism Speaks website 2Health News:Brief training program improves resident physicians' empathy with patients 2Health News:Brief training program improves resident physicians' empathy with patients 3Health News:Pneumococcal disease: More cases but fewer deaths 2Health News:Eye color may indicate risk for serious skin conditions 2
For the quantitative determination of Iron and IBC in serum. Colorimetric method utilizing ferrozine. Endpoint procedure measured at 560 nm. Linearity: 500 ug/dl....
HDL Cholesterol (PEG) Precip. Reagent + 5 ml of 50 mg/dl cholesterol std....
Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol...
... Intended for the quantitative ... plasma. Two vials, dry ... alphaketoglutarate. Uses NADPH to ... plasma compounds. Reaction: Enzymatic, ...
Medicine Products: